PMID- 36396790
OWN - NLM
STAT- MEDLINE
DCOM- 20230320
LR  - 20230320
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Print)
IS  - 0770-3198 (Linking)
VI  - 42
IP  - 4
DP  - 2023 Apr
TI  - Rheumatic diseases associated with alveolar hemorrhage: analysis of the national 
      inpatient sample.
PG  - 1177-1183
LID - 10.1007/s10067-022-06449-9 [doi]
AB  - OBJECTIVE: Diffuse alveolar hemorrhage (DAH) is a severe pulmonary complication 
      of numerous diseases, including rheumatic conditions. We have conducted an 
      observational study using inpatient data from the National Inpatient Sample to 
      study the relationship of DAH with rheumatic conditions along with their 
      descriptive characteristics. METHODS: An observational study was conducted on 
      hospitalizations in 2016-2018 with a principal diagnosis of DAH from the United 
      States National Inpatient Sample database. A multivariate logistic regression 
      analysis was performed to calculate adjusted odds ratios (OR(adj)) for risk 
      factors of DAH. RESULTS: A total of 5420 DAH hospitalizations were identified 
      among 90 million hospitalizations. Mortality in this group was found to be 24.3%. 
      Majority of patients admitted with DAH were white and male, with a mean age of 
      61.8 years and a mean LOS of 10.6 days. Multivariate analysis showed that 
      multiple rheumatic diseases were associated with DAH, including anti-neutrophil 
      cytoplasmic antibody-associated vasculitis (AAV) (OR(adj) 72.56) (95% C.I. 
      50.607-104.043), antiphospholipid antibody syndrome (APLS) (OR(adj) 6.51) (95% 
      C.I. 3.734-11.366), eosinophilic granulomatosis with polyangiitis (EGPA) (OR(adj) 
      7.13) (95% C.I. 1.886-26.926), Goodpasture's (OR(adj) 30.58) (95% C.I. 
      16.360-57.176), rheumatoid arthritis (RA) (OR(adj) 1.60) (95% C.I. 1.158-2.212), 
      sarcoidosis (OR(adj) 3.99) (95% C.I. 2.300-6.926), and systemic lupus (SLE) 
      (OR(adj) 5.82) (95% C.I. 3.993-8.481). CONCLUSION: Although DAH is a relatively 
      rare entity, it carries a very high mortality. Multiple rheumatic diseases were 
      associated with DAH hospitalizations including AAV, APLS, EGPA, Goodpasture's, 
      RA, sarcoidosis, and SLE. Key points * It is known that DAH carries a high 
      morbidity and mortality based on prior literature. However, large datasets on the 
      association of rheumatic diseases with DAH are lacking * This study identifies 
      the descriptive characteristics of patients admitted to the hospital with DAH * 
      This study also identifies the strength of association of rheumatic diseases with 
      DAH.
CI  - (c) 2022. The Author(s), under exclusive licence to International League of 
      Associations for Rheumatology (ILAR).
FAU - Kambhatla, Soumyasri
AU  - Kambhatla S
AUID- ORCID: 0000-0003-0786-9190
AD  - Rush University Medical Center, 1611 West Harrison Street, Suite 510, Chicago, 
      IL, 60612, USA. soumyasri.kambhatla@gmail.com.
FAU - Vipparthy, Sharath
AU  - Vipparthy S
AUID- ORCID: 0000-0002-1851-4830
AD  - Rush University Medical Center, 1611 West Harrison Street, Suite 510, Chicago, 
      IL, 60612, USA.
FAU - Manadan, Augustine M
AU  - Manadan AM
AUID- ORCID: 0000-0001-6200-5139
AD  - Rheumatology Program Director, Cook County Hospital, Rush University Medical 
      Center, 1611 West Harrison Street, Suite 510, Chicago, IL, 60612, USA.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20221118
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
SB  - IM
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Inpatients
MH  - *Churg-Strauss Syndrome/complications
MH  - *Granulomatosis with Polyangiitis/complications
MH  - Hemorrhage/complications
MH  - *Lung Diseases/complications/epidemiology
MH  - *Arthritis, Rheumatoid/complications/epidemiology
MH  - *Sarcoidosis/complications
MH  - *Lupus Erythematosus, Systemic/complications/epidemiology
MH  - Pulmonary Alveoli
PMC - PMC9672553
OTO - NOTNLM
OT  - ANCA vasculitis
OT  - Alveolar hemorrhage
OT  - Lupus
EDAT- 2022/11/18 06:00
MHDA- 2023/03/21 06:00
PMCR- 2022/11/18
CRDT- 2022/11/17 23:42
PHST- 2022/07/11 00:00 [received]
PHST- 2022/11/10 00:00 [accepted]
PHST- 2022/11/06 00:00 [revised]
PHST- 2022/11/18 06:00 [pubmed]
PHST- 2023/03/21 06:00 [medline]
PHST- 2022/11/17 23:42 [entrez]
PHST- 2022/11/18 00:00 [pmc-release]
AID - 10.1007/s10067-022-06449-9 [pii]
AID - 6449 [pii]
AID - 10.1007/s10067-022-06449-9 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2023 Apr;42(4):1177-1183. doi: 10.1007/s10067-022-06449-9. Epub 
      2022 Nov 18.